Literature DB >> 31988690

Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment? CME.

Jose Alvarez-Cardona1, Joshua Mitchell1, Daniel Lenihan1.   

Abstract

The acknowledgement of cardiovascular disease as one of the leading causes of mortality and morbidity among cancer survivors is the cornerstone of the growing field of cardio-oncology. Although standardizing treatment for any given disease is often considered ideal, it is important to recognize the value of pursuing a practical and personalized approach when caring for an oncology patient to minimize the risk of treatment-related cardiotoxicity. We hereby discuss a series of cases that illustrate the ways vascular toxicity can manifest in patients with cancer and, when appropriate, provide scientific evidence that supports clinical decision making. We also raise questions about the complex management of these patients while shedding light on future research in this growing field.
© 2019 Houston Methodist Hospital Houston, Texas.

Entities:  

Keywords:  arterial thrombosis; cardio-oncology; pulmonary embolism; superior vena cava syndrome; vascular toxicity; venous thromboembolism

Mesh:

Substances:

Year:  2019        PMID: 31988690      PMCID: PMC6977563          DOI: 10.14797/mdcj-15-4-289

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  33 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.

Authors:  Chiara Melloni; Allison Dunning; Christopher B Granger; Laine Thomas; Michel G Khouri; David A Garcia; Elaine M Hylek; Michael Hanna; Lars Wallentin; Bernard J Gersh; Pamela S Douglas; John H Alexander; Renato D Lopes
Journal:  Am J Med       Date:  2017-07-21       Impact factor: 4.965

Review 3.  Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management.

Authors:  Michelle L Griffith; Bipin N Savani; Jeffrey B Boord
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

4.  Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.

Authors:  Sonia S Anand; Francois Caron; John W Eikelboom; Jackie Bosch; Leanne Dyal; Victor Aboyans; Maria Teresa Abola; Kelley R H Branch; Katalin Keltai; Deepak L Bhatt; Peter Verhamme; Keith A A Fox; Nancy Cook-Bruns; Vivian Lanius; Stuart J Connolly; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2018-03-11       Impact factor: 24.094

5.  Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.

Authors:  Graeme J Hankey; Susanna R Stevens; Jonathan P Piccini; Yuliya Lokhnygina; Kenneth W Mahaffey; Jonathan L Halperin; Manesh R Patel; Günter Breithardt; Daniel E Singer; Richard C Becker; Scott D Berkowitz; John F Paolini; Christopher C Nessel; Werner Hacke; Keith A A Fox; Robert M Califf
Journal:  Stroke       Date:  2014-04-17       Impact factor: 7.914

6.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center.

Authors:  Shayna Sarosiek; Mark Crowther; J Mark Sloan
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

8.  Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients.

Authors:  Hyun S Kim; Stephen R Preece; James H Black; Luu D Pham; Michael B Streiff
Journal:  J Vasc Surg       Date:  2008-02       Impact factor: 4.268

9.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Authors:  Gary E Raskob; Nick van Es; Peter Verhamme; Marc Carrier; Marcello Di Nisio; David Garcia; Michael A Grosso; Ajay K Kakkar; Michael J Kovacs; Michele F Mercuri; Guy Meyer; Annelise Segers; Minggao Shi; Tzu-Fei Wang; Erik Yeo; George Zhang; Jeffrey I Zwicker; Jeffrey I Weitz; Harry R Büller
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

10.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.